Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2605)	1/18/2001 1:58:25 PM
From: Mark Bong	Read Replies (2) \| Respond to of 52153

Peter, I listened to the Biogen CC as well as their presentation at the JPMorgan Healthcare conference. I feel that BGEN is a good buy now because I believe that Avonex sales will hold up well for a number of years and the blockbuster potential of Amevive is not reflected in the stock price. I also feel that their pipeline is improving as they indicated that they would put three new drugs in the clinic this year. A yet unknown but potentially positive factor is the indication from Jim Mullen that they would be announcing a few more deals similar to the ELAN deal in the next few months. I see moderate downside risk with this stock, but good to significant upside potential from here. With good news, this stock will take off sometime later this year. Now is probably a good time to load up. I own Jan 02 60 leaps, which I bought for 12-15 a share a while back as well as shares in my IRA and other accounts. JMHO Mark